Effects of Semaglutide on Kidney Parameters in Patients with Obesity and Nondiabetic CKD
Hiddo Jan L. Heerspink, José Luis Górriz(Universitat de València), Annemarie B. van der Aart(Martini Ziekenhuis), David Z.I. Cherney(University Health Network), Christoph Wanner(Universitätsklinikum Würzburg), Ellen M. Apperloo(Dialyse Centrum Groningen), Secundino Cigarrán(Hospital Ruber Internacional), Josep M. Cruzado, Roland E. Schmieder(Friedrich-Alexander-Universität Erlangen-Nürnberg), Gozewijn D. Laverman(Ziekenhuis Groep Twente), María José Soler(Mayo Clinic), Sofia B. Ahmed(University of Alberta), Jacobien C. Verhave(Rijnstate Hospital), Niels Jongs(University Medical Center Groningen)
Cited by 0
Related Papers
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|969
CKD Prevalence Varies across the European General Population
|Journal of the American Society of Nephrology|2015|588
Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
|New England Journal of Medicine|2010|574